Release issued 28th April 2006

ALLIANCE PHARMA PLC ("Alliance" or "the Company")

London symposium on Melatonin

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, is pleased to announce that it is today sponsoring a symposium at the Royal Society of Medicine focussed on melatonin, the naturally occurring hormone that controls the sleep-wake cycle, and its potential in the treatment of sleep disorders.

Alliance Pharma has developed a melatonin-based treatment, Posidorm, for sleep disorders which is currently undergoing Phase III trials.

Today's symposium, titled An Exploration: Melatonin and its Role in Sleep, will include a series of presentations by key opinion leaders and scientific and medical experts on melatonin's medical potential across a wide range of patient populations including shiftworkers, the elderly and the blind and also examine its potential to treat jet-lag.

The symposium will be chaired by Professor Josephine Arendt, Emeritus Professor of Endocrinology, University of Surrey, and attendees will include neurologists, occupational health specialists, geriatricians and opthalmologists.

Key presentations at the symposium include:

• Physiology and Pharmacology of Melatonin, Prof Josesphine Arendt

• Shift Work, Sleep and Sleepiness, Prof Torbjorn Akerstedt

• Resetting the Circadian Clock: Solutions for Jet Lag and Shift Work, Prof Charmane Eastman

• Melatonin in Circadian Rhythm Sleep Disorders of the Blind, Prof Debra Skene

• Melatonin in Elderly Patients, Dr Eus van Someren

• Melatonin in Neurodisability, Dr Richard Appleton

Commenting on the symposium, John Dawson, Alliance Pharma's Chief Executive, said: "We are delighted to have the opportunity to bring together such a distinguished panel of international experts in sleep and sleep disorders and to further the understanding of the role of melatonin, which we believe has significant potential both medically and commercially."

Professor Arendt commented: "I am very pleased to be chairing this important multidisciplinary meeting, which is a step forward in bringing melatonin to the market as a medicine to help the different groups that can benefit."

For further information:

Alliance Pharma plc + 44 (0) 1249 466966

John Dawson, Chief Executive Maddy Scott, Finance Director www.alliancepharma.co.uk

Buchanan Communications + 44 (0) 20 7466 5000 Mark Court/Lisa Baderoon/Rebecca Skye Dietrich

Notes to editors

About Alliance Pharma Alliance Pharma, founded in 1996, is an AIM listed emerging speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The company has a strong track record of acquiring the rights to established niche brands and owns, or shares, the rights to 30 branded pharmaceutical products and continues to explore opportunities to expand the range.

Alliance Pharma's products are prescribed in the treatment of a wide range of conditions and include brands used in periodontitis (a serious gum disease), the prevention of heart disease, in Parkinson's disease, in nutrition, in nasal infections, in the treatment of dermatological conditions and in childbirth. Alliance Pharma's sales are mainly prescription driven. Its products are distributed to hospitals directly and to pharmaceutical wholesalers which service both hospital and retail pharmacies with their prescription requirements.

Alliance Pharma is also developing novel products for sleep disorders and the induction of labour.

Alliance Pharma joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.

(22nd May 2006) Leading distributor signed in Italy for Periostat

(18th May 2006) Dermatology Acquisition

(9th February 2006) Alliance acquires Hydromol from Ferndale

(3rd November 2005) Alliance Pharma PLC - Product Disposal

(29th July 2005) Leading distributor signed in Turkey for Periostat(R)